World Journal of Nephrology

Letter to the Editor: Vitamin D deficiency and post-transplant diabetes in kidney recipients - opportunity for risk stratification and intervention

Vitamin D deficiency is highly prevalent worldwide, including in South Asia, and may contribute to dysglycemia by affecting insulin secretion, insulin sensitivity, and inflammation. Observational studies in the general population link lower 25-hydroxyvitamin D concentrations to a higher risk of incident type 2 diabetes...

World Journal of Nephrology

Diabetic kidney disease within the framework of cardio-kidney-metabolic health: a paradigm shift

A phenotype-driven framework for sequencing combination therapy based on each patient’s dominant pathophysiologic driver as a hypothesis-generating alternative to uniform add-on strategies is proposed and the future direction of DKD management and the need for integrated multidisciplinary approaches aimed at improving...

Periostin in diabetic kidney disease: mechanistic insights, biomarkers, and therapeutic perspectives

Diabetic kidney disease (DKD) is among the most common and severe microvascular complications of diabetes and represents a leading cause of end-stage renal disease (ESRD) worldwide. Currently, although strict glycemic and blood pressure control, together with the use of renin–angiotensin system inhibitors, sodium-gluco...

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel.

Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as an additional pillar of cardiorenal therapy alongside...

Association of SGLT2 inhibitors and GLP-1 receptor agonists with mortality and renal outcomes in patients with diabetes and chronic kidney disease: the diabetic nephropathy management and outcome (DINAMO) study

Patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) are at high risk for kidney failure and death. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) improve cardiovascular and renal outcomes; yet, their real-world use in patients with diabe...